other · Healthcare · Biotechnology
CAPR
6.57-0.43 -6.08%Past year
Loading chart…
Loading financials…
Company snapshot
- Ticker
- CAPR
- Exchange
- NMS
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $1.14B
- Employees
- 231
- Currency
- USD
- Website
- https://www.capricor.com
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also…
Latest coverage
No coverage yet — articles appear here automatically as press releases are published.
Related other stocks
Quotes & data
Follow Capricor Therapeutics, Inc. (CAPR) across major market-data sources.